Since Bcl3, PD-L1 and IL-8 promote tumorigenesis, combinatorial strategies targeting the IFNγ-induced Bcl3, PD-L1 and IL-8 expression in ovarian cancer may enhance the antitumor effects of cancer immunotherapies. The gene discussed is BCL3; the disease is ovarian cancer.